Takeda's oral Velcade successor enters Phase III for myeloma
This article was originally published in Scrip
Executive Summary
Takeda and its Millennium oncology operation have begun a Phase III development programme for ixazomib citrate (MLN9708), the first oral proteasome inhibitor to enter clinical trials and a possible successor to the firms' big-selling multiple myeloma drug Velcade (bortezomib).